SCHEMBL479208

SCHEMBL479208

CN(c1cnc2nc(N)nc(N)c2n1)c1ccccc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DHFR P00374 9/20 0.45
NCOA3 Q9Y6Q9 1/20 0.41
PIK3CG P48736 2/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7242695 0.81 NCOA3 (0.58) DHFRNCOA3
SCHEMBL480956 0.79 PIK3CG (0.42) DHFRNCOA3PIK3CGPIK3CAPIK3CB
Water SCHEMBL9320891 0.78 DHFR (0.49) DHFRNCOA3
SCHEMBL479180 0.77 DHFR (0.48) DHFRNCOA3PIK3CGPIK3CAPIK3CB
SCHEMBL27848859 0.76
SCHEMBL479322 0.74 DHFR (0.40) DHFRNCOA3
SCHEMBL479157 0.74 DHFR (0.45) DHFRNCOA3
SCHEMBL479193 0.73 DHFR (0.45) DHFRNCOA3
SCHEMBL480783 0.72 DHFR (0.42) DHFRNCOA3
SCHEMBL480784 0.72 DHFR (0.42) DHFRNCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283219-A1 DIAMINOPTERIDINE DERIVATIVES BIORELIX, INC. 2012-11-08 US disclosed
EP-2410856-A1 DIAMINOPTERIDINE DERIVATIVES Biorelix, Inc. (US) 2012-02-01 EP disclosed
WO-2010110907-A1 DIAMINOPTERIDINE DERIVATIVES BIORELIX, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283219-A1 DIAMINOPTERIDINE DERIVATIVES MPO, AOC1, DCTD DHFR 19/4885NCOA3 3745/4885PIK3CG 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.